Analystreport

Marinus Pharmaceuticals Inc (NASDAQ: MRNS) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $4.50 price target on the stock.

Marinus Pharmaceuticals, Inc.  (MRNS) 
Last marinus pharmaceuticals, inc. earnings: 11/6 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.marinuspharma.com/investor-relations